Ricevi le ultime notizie sulle azioni GRI Bio con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di GRI

Ultime notizie per

GRI BIO INC

Cohen & Steers Global Realty Majors ETF

GRI Bio

GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.

GRI Bio Inc

First Trust NASDAQ Clean Edge Smart Grid Infrastructure Index Fund

VictoryShares International Free Cash Flow Growth ETF

Grid+

GRIID Infrastructure Inc

Grin

Press Releases

GRI Bio Completes Enrollment in Phase 2a Study of GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis ("IPF")

Events

JTC Team Announces Participating Line Up for the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference

News

JTC Team Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference Now Live

GRI Bio Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference

GRI Bio Reports 6-Week Interim Biomarker Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis ("IPF")

GRI Bio CEO, Marc Hertz, Participates in Virtual Investor "What This Means" Segment

GRI Bio to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

JTC Team Companies to Present in Webull Corporate Connect Webinar Series: Biotech/MedTech on August 19-21, 2025

GRI Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference

GRI Bio Reports 6-Week Interim Lung Function Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis ("IPF")

AKTX

AMIX

CNSP

MBRX

NUWE

NVNO

OTLK

PALI

SNTI

Aditxt

Aptevo Therapeutics

Bone Biologics

Biodexa Pharmaceuticals plc - American Depositary Shares

Biodexa Pharmaceuticals

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Hldgs

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics

Entero Therapeutics

Galecto

Indaptus Therapeutics, Inc. - Common Stock

Indaptus Therapeutics

Pasithea Therapeutics Corp. - Common Stock

Pasithea Therapeutics

Oragenics

Onconetix

Polyrizon

PharmaCyte Biotech

Protagenic Therapeutics, Inc. - Common Stock

Protagenic Therapeutics

Quoin Pharmaceuticals, Ltd. - American Depositary Shares

Quoin Pharmaceuticals

Revelation Biosciences, Inc. - Common Stock

Revelation Biosciences

Sunshine Biopharma

Scinai Immunotherapeutics Ltd. - American Depositary Shares

Scinai Immunotherapeutics

Shuttle Pharmaceuticals Holdings, Inc. - common stock

Shuttle Pharmaceuticals

Salarius Pharmaceuticals, Inc. - Common Stock

Salarius Pharmaceuticals

Spruce Biosciences

Alaunos Therapeutics, Inc. - Common Stock

Comments

GRI Bio Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO